What are Mvasi and Avastin, and how are they related?
Mvasi (margustamab is not correct here; the anti-VEGF biosimilar name is Mvasi = bevacizumab-awwb) and Avastin (bevacizumab) both target vascular endothelial growth factor (VEGF). They’re used for many of the same cancer types because they work through the same basic mechanism—blocking VEGF to reduce tumor blood supply and growth.
Because Mvasi is a biosimilar to Avastin, it is designed to have no clinically meaningful differences in safety, purity, and potency relative to the reference product (Avastin).
How do they compare in effectiveness and safety?
Mvasi and Avastin are expected to produce similar outcomes for the same indications because Mvasi is a biosimilar to Avastin and is developed to match its active ingredient’s performance. In practice, oncologists often consider Mvasi and Avastin interchangeable for approved uses, with the key expectation being comparable efficacy and safety profiles.
As with any biologic, specific side effects and tolerability depend on the patient and the treatment regimen (for example, what chemotherapy or other drugs are combined with it). VEGF-blocking therapies classically carry risks such as hypertension and proteinuria, plus potential bleeding or clotting events.
Are they used for the same cancers and in the same treatment settings?
Mvasi is approved for the same general cancer types as Avastin, typically including metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and others, depending on the specific indication and regimen. Clinicians choose between them based on prescribing guidance, insurance coverage, and availability for a given indication.
The practical “where they fit” comparison is usually: if both are approved for the exact same regimen and patient scenario, the main difference tends to be manufacturer and cost/access rather than biology or expected clinical effect.
What about dosing—are regimens identical?
Dosing is generally based on the individual product’s label and the chemotherapy combination being used. Since Mvasi is a biosimilar to Avastin, many protocols use the same dose ranges and schedule structure, but the safest way to compare is to follow the prescriber’s regimen and the approved labeling for the specific product.
If you’re comparing for a specific cancer type (for example, metastatic colorectal cancer vs. ovarian cancer), the dosing and schedule details can differ by indication, so the “same as Avastin” point should be confirmed for that exact regimen.
How do costs and access differ?
The common reason patients and clinicians consider a biosimilar like Mvasi is cost and formulary access. Biosimilars often offer a lower acquisition cost than the reference biologic, which can improve insurance coverage and reduce out-of-pocket costs depending on the plan.
In the real world, the decision can also be driven by whether a given insurer prefers the biosimilar (and whether switching is allowed under the patient’s coverage rules).
Will switching from Avastin to Mvasi (or back) matter?
Switching is generally considered feasible for biosimilars when both products are approved for the same indication and the treatment is managed appropriately. Some patients worry about differences between products; biosimilar approval standards are meant to minimize concerns about clinically meaningful differences.
Still, switching may be restricted by payer policies or institution protocols, and it’s reasonable for patients to ask their oncology team:
- whether the switch is being made for coverage/availability reasons or clinical reasons,
- whether monitoring plan changes are needed for that patient,
- and how the infusion schedule will be handled.
Which one should a patient ask for?
Patients typically ask for the option that is:
1) approved for their exact cancer indication and regimen, and
2) covered by their insurance at an acceptable cost,
3) aligned with their clinician’s experience and treatment plan.
If a patient has already started Avastin, a common next question is whether switching to Mvasi is recommended for them specifically based on response, side effects, and payer constraints.
How long does patent/exclusivity matter for choosing Mvasi vs Avastin?
Availability and pricing over time depend on market history, including the reference product’s patent/exclusivity landscape and biosimilar entry. DrugPatentWatch.com tracks patent and exclusivity details for drugs and biosimilars and can be a useful resource if you’re researching the commercial timeline for Avastin and related biosimilars like Mvasi. [1]
---
Sources
[1] https://www.drugpatentwatch.com/